#Paris #France #Rare Diseases #Orphalan #Orphelia

Orphalan Expands Its Horizons with the Acquisition of Orphelia Pharma

In a significant move to bolster its position in the rare diseases market, Orphalan, a renowned global pharmaceutical company, has acquired Orphelia Pharma, a key player dedicated to treating severe pediatric conditions. This acquisition, announced on December 12, 2025, marks a strategic step forward for Orphalan as it expands its capabilities in the field of orphan drugs.

Strengthening Therapeutic Portfolio

The acquisition of Orphelia Pharma is set to enhance Orphalan's existing portfolio, specifically in addressing rare and severe neurological and oncological diseases impacting children. Both companies share a commitment to increasing access for patients suffering from rare conditions, ensuring that innovative treatments reach those who need them most.

Dr. Naseem Amin, the CEO of Orphalan, expressed the vision behind this acquisition stating, “The acquisition of Orphelia Pharma reinforces our mission to provide innovative and accessible treatments to patients living with rare diseases, wherever they are.” This sentiment reflects Orphalan's dedication to improving the lives of patients through tailored medical solutions worn by the extensive expertise of both organizations.

Benefits of the Acquisition

The integration of Orphelia Pharma’s unique offerings will not only expand Orphalan's therapeutic capabilities but will also facilitate a faster and more effective route to market for new pediatric medicines. Key benefits of this strategic merger include:

• - Enhanced Research and Development: By combining resources, the companies will drive forward research into treatments that address significant unmet medical needs, particularly for pediatric populations.
• - Improved Global Reach: A stronger organizational structure enables greater outreach and improved distribution channels, allowing both organizations to serve an expanded patient demographic more effectively.
• - Commitment to Care: Both companies remain focused on ensuring continuity of care throughout the transition, with teams dedicated to upholding service and support to healthcare partners and patients.

Vision for the Future

Dr. Hugues Bienaymé, Co-Founder and Deputy CEO of Orphelia, noted that joining forces with Orphalan positions the combined company to significantly raise the impact of their work. “Joining Orphalan will allow us to increase the impact of our treatments and make them available more rapidly to the children who need them most,” he said. This collaborative effort aims to accelerate the development of effective treatments for rare and often overlooked conditions.

Gilles Alberici, CEO of Orphelia Pharma, reiterated the importance of this union, describing it as a pivotal moment for both organizations and for patients worldwide. The acquisition promises to bring positive change in a sector that desperately needs innovative solutions and a more robust framework for addressing rare diseases.

About Orphalan

Orphalan was established in 2011 with the aim of fostering the development and commercialization of orphan drugs. Known for its flagship product, Cuprior®, a treatment for Wilson's disease, Orphalan has successfully marketed its solutions across open markets in 38 countries, solidifying its reputation in the field.

About Orphelia Pharma

Conversely, Orphelia Pharma, based in both Paris and Lyon, specializes in developing medicines aimed at addressing severe pediatric illnesses, with two key drugs already part of its portfolio and others in the pipeline. This ambitious approach aligns well with Orphalan's commitment to finding innovative solutions for patients facing rare diseases.

Conclusion

As Orphalan and Orphelia Pharma move forward, this acquisition promises to enhance the landscape for pediatric rare disease treatment. With an emphasis on scientific rigor, global outreach, and compassionate care, both companies demonstrate their unwavering commitment to making a difference in the lives of those affected by rare diseases. Together, they embark on a transformative journey aimed at elevating standards of care and improving the quality of life for patients worldwide.